Lacosamide-induced sinus node dysfunction followed by severe agranulocytosis

BACKGROUND: Lacosamide (LCM) is the antiepileptic drug approved by the U.S. Food and Drug Administration in 2008 that facilitates slow activation of the voltage-gated sodium channels. Neutropenia and cardiac events including sinus node dysfunction (SND) and atrioventricular block have been previousl...

Descripción completa

Detalles Bibliográficos
Autores principales: Shibata, Makoto, Hoshino, Reona, Shimizu, Chisato, Sato, Masayuki, Furuta, Natsumi, Ikeda, Yoshio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185934/
https://www.ncbi.nlm.nih.gov/pubmed/34102997
http://dx.doi.org/10.1186/s12883-021-02253-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185934/
https://www.ncbi.nlm.nih.gov/pubmed/34102997
http://dx.doi.org/10.1186/s12883-021-02253-1

Ejemplares similares